Testing effectiveness (Phase 2)Study completedNCT02163577
What this trial is testing
Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)
Who this might be right for
X-linked Hypophosphatemia
Kyowa Kirin, Inc. 52